ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05346354
- Locations
- 🇪🇸
Research Site, Esplugues de Llobregat, Spain
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319912
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05314231
- Locations
- 🇰🇷
Clinical Trial Site 2, Anyang-Si, Gyeonggi-do, Korea, Republic of
🇰🇷Clinical Trial Site 1, Seoul, Korea, Republic of
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05307978
- Locations
- 🇬🇧
Clinical Trial Site, Harrow, United Kingdom
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05303324
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of a Single Dose of ALXN1210 in Healthy Participants
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05288660
- Locations
- 🇨🇦
Clinical Trial Site, Montréal, Canada
A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05288816
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: ALXN1210 SCDrug: ALXN1210 IV
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05288829
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05288673
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath